Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christina Reith

Showing results (11-20 of 34) with videos related to

Pageof 4
Sort By:
Kidney International Reports|August 4, 2023
Impact of outcome adjudication in kidney disease trials: observations from the Study of Heart and Renal Protection (SHARP)William G Herrington, Charlie Harper, Natalie Staplin, et al.
Heart (British Cardiac Society)|August 7, 2017
A policy model of cardiovascular disease in moderate-to-advanced chronic kidney diseaseIryna Schlackow, Seamus Kent, William Herrington, et al.
Kidney International Reports|June 2, 2018
Impact of CKD on Household IncomeRachael L Morton, Iryna Schlackow, Alastair Gray, et al.
The British Journal of General Practice : the Journal of the Royal College of General Practitioners|February 19, 2024
Long-term cardiovascular risks and the impact of statin treatment on socioeconomic inequalities: a microsimulation modelRunguo Wu, Claire Williams, Junwen Zhou, et al.
Plos One|January 26, 2012
Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy, Jonathan R Emberson, Patricia M Kearney, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|March 12, 2014
Evaluating the contribution of the cause of kidney disease to prognosis in CKD: results from the Study of Heart and Renal Protection (SHARP)Richard Haynes, Natalie Staplin, Jonathan Emberson, et al.
BMC Nephrology|May 1, 2015
What is the impact of chronic kidney disease stage and cardiovascular disease on the annual cost of hospital care in moderate-to-severe kidney disease?Seamus Kent, Iryna Schlackow, Jingky Lozano-Kühne, et al.
Pharmacoeconomics|February 24, 2023
Prediction Models for Individual-Level Healthcare Costs Associated with Cardiovascular Events in the UKJunwen Zhou, Runguo Wu, Claire Williams, et al.
Health Technology Assessment (Winchester, England)|December 7, 2024
Assessing long-term effectiveness and cost-effectiveness of statin therapy in the UK: a modelling study using individual participant data setsBorislava Mihaylova, Runguo Wu, Junwen Zhou, et al.
The Lancet Regional Health. Europe|March 29, 2024
Lifetime effects and cost-effectiveness of standard and higher-intensity statin therapy across population categories in the UK: a microsimulation modelling studyBorislava Mihaylova, Runguo Wu, Junwen Zhou, et al.
Pageof 4

Showing results (11-20 of 34) with videos related to

Sort By:
Pageof 4
Kidney International Reports|August 4, 2023
Impact of outcome adjudication in kidney disease trials: observations from the Study of Heart and Renal Protection (SHARP)William G Herrington, Charlie Harper, Natalie Staplin, et al.
Heart (British Cardiac Society)|August 7, 2017
A policy model of cardiovascular disease in moderate-to-advanced chronic kidney diseaseIryna Schlackow, Seamus Kent, William Herrington, et al.
Kidney International Reports|June 2, 2018
Impact of CKD on Household IncomeRachael L Morton, Iryna Schlackow, Alastair Gray, et al.
The British Journal of General Practice : the Journal of the Royal College of General Practitioners|February 19, 2024
Long-term cardiovascular risks and the impact of statin treatment on socioeconomic inequalities: a microsimulation modelRunguo Wu, Claire Williams, Junwen Zhou, et al.
Plos One|January 26, 2012
Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy, Jonathan R Emberson, Patricia M Kearney, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|March 12, 2014
Evaluating the contribution of the cause of kidney disease to prognosis in CKD: results from the Study of Heart and Renal Protection (SHARP)Richard Haynes, Natalie Staplin, Jonathan Emberson, et al.
BMC Nephrology|May 1, 2015
What is the impact of chronic kidney disease stage and cardiovascular disease on the annual cost of hospital care in moderate-to-severe kidney disease?Seamus Kent, Iryna Schlackow, Jingky Lozano-Kühne, et al.
Pharmacoeconomics|February 24, 2023
Prediction Models for Individual-Level Healthcare Costs Associated with Cardiovascular Events in the UKJunwen Zhou, Runguo Wu, Claire Williams, et al.
Health Technology Assessment (Winchester, England)|December 7, 2024
Assessing long-term effectiveness and cost-effectiveness of statin therapy in the UK: a modelling study using individual participant data setsBorislava Mihaylova, Runguo Wu, Junwen Zhou, et al.
The Lancet Regional Health. Europe|March 29, 2024
Lifetime effects and cost-effectiveness of standard and higher-intensity statin therapy across population categories in the UK: a microsimulation modelling studyBorislava Mihaylova, Runguo Wu, Junwen Zhou, et al.
Pageof 4